RadioClash
Develops Electro-Embolizer Device for electroporation therapy targeting pancreatic, liver, and bone cancers.
Website: https://www.radioclash.co/
Cover Block
PUBLIC
| Name | RadioClash |
| Tagline | Develops Electro-Embolizer Device for electroporation therapy targeting pancreatic, liver, and bone cancers. |
| Headquarters | Houston, United States |
| Founded | 2020 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
| Total Disclosed | $1,000,000 |
Links
PUBLIC
- Website: https://www.radioclash.co/
- LinkedIn: https://www.linkedin.com/company/radioclash/
Executive Summary
PUBLIC RadioClash is a Houston-based medical device startup developing a novel, minimally invasive probe for treating late-stage solid tumors, a high-stakes clinical area where incremental improvements in safety and efficacy can command significant value. Founded in 2020 by Dr. John Qiao, the company is building the Electro-Embolizer Device (EED), which aims to deliver combination electroporation therapy (CET) to tumors in the pancreas, liver, and bones [Voyage Houston Magazine]. The founding story is rooted in academic competition, with the company winning the 2021 Columbia-CareOne Healthcare Innovation Challenge [Columbia Entrepreneurship, Nov 2021].
Dr. Qiao serves as CEO, with Duane Bester as CTO [YouTube, Sep 2025]. The company has secured $1 million in seed capital, though the investor syndicate is not publicly named [SignalBase]. RadioClash's business model, as presented by the company, targets a 96% gross margin, a figure that remains unverified by independent sources [YouTube, Sep 2025]. The company has engaged Biotex, a Houston MedTech firm, for commercialization support, indicating an early strategic partnership to navigate the complex regulatory and sales pathways inherent to medical devices.
For investors, the next 12-18 months will be critical for validating several key assumptions. Progress through preclinical studies and toward initial human trials will be the primary technical milestone to monitor. Concurrently, the ability to attract follow-on funding from institutional life science investors, and to move beyond local press coverage to secure recognition in vertical trade publications, will serve as important signals of external validation and commercial traction. Data Accuracy: YELLOW -- Core facts like founding, funding amount, and product focus are corroborated by multiple sources, but key operational and financial claims lack independent verification.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed (total disclosed ~$1,000,000) |
Company Overview
PUBLIC
RadioClash is a Houston-based medical device startup founded in 2020 by Dr. John Qiao, who serves as the company's Chief Executive Officer [Startup Columbia, 2022]. The company's formation appears to have been driven by Qiao's clinical focus, with the venture gaining early validation by winning the 2021 Columbia-CareOne Healthcare Innovation Challenge [Columbia Entrepreneurship, Nov 2021]. Duane Bester is listed as a co-founder and holds the title of Chief Technology Officer [The Org, Unknown].
Key operational milestones for the company are limited to its initial fundraising and a strategic partnership. RadioClash secured a seed funding round of $1,000,000, though the specific date and lead investor are not publicly disclosed [SignalBase]. In a subsequent development, the company announced a partnership with Biotex, a Houston-based MedTech firm, to provide strategic guidance and commercialization support for its device [Columbia Entrepreneurship, Nov 2021].
Data Accuracy: YELLOW -- Core facts (founding year, founder names, seed round amount) are corroborated across multiple sources, but key details like funding date and investor identity rely on a single report.
Product and Technology
MIXED RadioClash’s core product is the Electro-Embolizer Device (EED), a surgical probe designed for a specific type of cancer treatment. The company describes the EED as a minimally invasive instrument that delivers combination electroporation therapy (CET) to solid tumors [Voyage Houston Magazine]. This approach pairs the application of targeted electrical pulses, a process known as electroporation, with the delivery of small-molecule drugs directly into the tumor site [Columbia Entrepreneurship, Nov 2021]. The initial clinical focus is on late-stage pancreatic, liver, and bone cancers, where treatment options are often limited and invasive.
The technical premise is to improve upon existing ablation techniques. By using electrical fields to create temporary pores in cancer cell membranes, the method aims to increase the intracellular uptake and efficacy of co-administered therapeutic agents. The device itself is positioned as a tool for interventional radiologists and oncologists, intended for use in procedures like percutaneous needle insertion. A company video from September 2025 claims the associated business model carries a 96% gross margin, though this figure is unverified by independent sources [YouTube, Sep 2025] [PUBLIC].
Public details on the device’s development stage or regulatory pathway are absent. The company has announced a partnership with Biotex, a Houston-based MedTech firm, for strategic guidance and commercialization support, which suggests the technology is still in a pre-clinical or early clinical development phase [Columbia Entrepreneurship, Nov 2021]. No information on clinical trials, FDA submissions, or specific technical specifications like pulse parameters or drug compatibility is available in public materials.
Data Accuracy: YELLOW -- Product concept is described in company and university materials, but key technical and regulatory details are not publicly disclosed. The high-margin claim is sourced solely from a company video.
Market Research and Opportunity
MIXED
RadioClash's ambition to treat late-stage solid tumors with a minimally invasive device places it at the intersection of two large, established, and growing healthcare markets: interventional oncology and the global ablation device sector. The primary demand driver is the persistent clinical need for more effective and tolerable treatments for cancers like pancreatic and liver, where five-year survival rates remain low and systemic therapies often fall short [Columbia Entrepreneurship, Nov 2021]. The company's focus on combination therapy, which pairs a physical ablation technique with drug delivery, aligns with a broader industry trend toward multimodal approaches intended to improve patient outcomes and potentially reduce hospital stays.
Quantifying the specific addressable market for RadioClash's Electro-Embolizer Device is challenging due to the absence of public, third-party market sizing for the niche of combination electroporation therapy. However, analogous markets provide a frame of reference. The global market for tumor ablation devices, which includes radiofrequency, microwave, and cryoablation technologies, was valued at approximately $1.4 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of around 10% through the decade, driven by the rising incidence of cancer and a shift toward minimally invasive procedures [analogous market, Grand View Research, 2024]. The interventional oncology segment, which encompasses image-guided therapies, represents a multi-billion dollar opportunity on its own.
Key adjacent and substitute markets include traditional surgical resection, radiation therapy (including stereotactic body radiation therapy, or SBRT), and systemic chemotherapy or immunotherapy. RadioClash's proposed value proposition of faster recovery and a minimally invasive approach positions it as a potential alternative or adjunct to these established modalities, particularly for patients who are not optimal candidates for surgery. A significant macro force shaping this opportunity is the ongoing pressure on healthcare systems to reduce costs and improve patient throughput, which could favor outpatient-capable procedures with shorter recovery times.
Regulatory forces present both a hurdle and a potential moat. The path to market in the United States requires clearance or approval from the Food and Drug Administration (FDA), a process that demands substantial clinical evidence of safety and efficacy. Successfully navigating this process would grant the company a period of market exclusivity, but the lack of disclosed regulatory milestones or clinical trial data makes the timeline and probability of success difficult to assess from public information.
| Metric | Value |
|---|---|
| Global Tumor Ablation Devices Market (2023) | 1400 $M |
| Projected CAGR (2024-2030) | 10 % |
The projected growth in the broader ablation market underscores the underlying tailwind, but RadioClash's specific SAM remains unquantified and is contingent on clinical validation and physician adoption for its chosen indications.
Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party reports for the ablation device sector; RadioClash's specific addressable market is not publicly quantified.
Competitive Landscape
MIXED, RadioClash's competitive position is defined not by a crowded field of direct device peers, but by its attempt to carve a niche within the established interventional oncology ecosystem, where its primary competition comes from entrenched therapeutic modalities rather than startup rivals.
Given the absence of named direct competitors in the structured sources, a formal comparison table is omitted. The competitive analysis proceeds from the available public positioning.
RadioClash's immediate competitive map is segmented by therapeutic approach. The company's Electro-Embolizer Device (EED) targets late-stage solid tumors in the pancreas, liver, and bones [Columbia Entrepreneurship, Nov 2021]. In these clinical settings, the primary alternatives are not other electroporation startups, but established ablation technologies and systemic treatments. Incumbent modalities include radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, which are widely available and reimbursed. Adjacent substitutes include external beam radiation therapy (including stereotactic body radiation therapy, or SBRT) and systemic chemotherapy or immunotherapy. These represent the standard-of-care options against which any new device must prove superior efficacy, safety, and cost-effectiveness to gain adoption.
Where RadioClash claims a defensible edge today is in its specific combination therapy approach. The company focuses on combination electroporation therapy (CET), which aims to enhance the delivery and efficacy of co-administered small-molecule drugs [Voyage Houston Magazine]. This positions it against generic electroporation systems, which may not be optimized for concurrent drug delivery. The edge is currently perishable, however, as it rests on proprietary device design and unproven clinical outcomes rather than on protected intellectual property, exclusive data, or regulatory moats that have been publicly disclosed. The partnership with Biotex for commercialization support provides a channel advantage, but it is a service relationship, not an owned distribution asset [Columbia Entrepreneurship, Nov 2021].
The company is most exposed in two areas. First, to large medical device incumbents with deep R&D budgets and established sales forces in interventional radiology, such as Boston Scientific or Medtronic, which could develop or acquire similar combination therapy platforms. Second, to the regulatory and clinical trial burden; without published trial data or a clear FDA pathway, the device remains a development-stage concept, vulnerable to delays that well-capitalized competitors could exploit.
The most plausible 18-month competitive scenario hinges on clinical validation and partnership depth. If RadioClash can publish compelling pre-clinical or early clinical data demonstrating superior tumor response rates for its CET approach, it becomes an attractive acquisition target for a mid-sized device company looking to expand in oncology ablation. The winner in this scenario would be a strategic acquirer gaining a novel pipeline asset. The loser would be RadioClash operating as a standalone entity if it fails to secure the next round of funding needed to reach those clinical milestones, given the capital-intensive nature of medical device development and the current lack of named institutional investors on its cap table.
Data Accuracy: YELLOW, Competitive positioning is inferred from company claims and standard market alternatives; no direct competitor profiles are publicly confirmed.
Opportunity
PUBLIC The prize for RadioClash is a multi-billion dollar position in the interventional oncology market, contingent on successfully navigating a high-stakes clinical and regulatory path. This analysis outlines the plausible, evidence-based scenarios that could lead there.
The headline opportunity is to become the standard-of-care ablation platform for inoperable solid tumors, starting with pancreatic cancer. The company's focus on combination electroporation therapy (CET) for late-stage disease targets a critical unmet need where surgical resection is often impossible and systemic therapies have limited efficacy [Columbia Entrepreneurship, Nov 2021]. If the Electro-Embolizer Device (EED) demonstrates superior safety and efficacy in clinical trials, it could shift treatment paradigms for a patient population with few good options, establishing a new category within interventional radiology suites. The partnership with Biotex, a firm with over two decades of commercialization experience, provides a tangible bridge from development to clinical adoption, suggesting a path beyond the lab [Columbia Entrepreneurship, Nov 2021].
Two or three growth scenarios, each named
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Niche Dominance in Pancreatic Cancer | The EED becomes the preferred ablation modality for locally advanced pancreatic cancer, capturing a majority share in a high-margin procedural segment. | Successful completion of a pivotal clinical trial leading to FDA 510(k) clearance or De Novo classification. | The company's initial focus is precisely on this indication [Columbia Entrepreneurship, Nov 2021], and the reported 96% gross margin model suggests a financially sustainable entry point [YouTube, Sep 2025]. |
| Platform Expansion into Adjacent Cancers | Following initial clearance, the device gains indications for liver and bone metastases, becoming a multi-indication tool for interventional oncologists. | Publication of positive pilot study data in liver tumors, leveraging the same core electroporation mechanism. | The technology is described as targeting pancreatic, liver, and bone cancers from inception [Columbia Entrepreneurship, Nov 2021], implying a platform design, not a single-use device. |
What compounding looks like centers on clinical data as a moat. Each successful procedure generates proprietary data on tumor response, dosing, and patient outcomes. This dataset could refine treatment protocols, support submissions for additional indications, and create a barrier for entrants lacking real-world evidence. Early adoption by key opinion leaders in interventional radiology, hinted at through podcast appearances by the founder [BackTable], could accelerate this flywheel by generating influential case studies and peer-reviewed publications that drive broader hospital adoption.
The size of the win can be framed by looking at comparable acquisitions in the interventional oncology space. For example, Johnson & Johnson acquired NeuWave Medical, a developer of microwave ablation systems, for an undisclosed sum in 2016 to bolster its Ethicon business. More recently, Boston Scientific acquired the surgical business of Lumenis for $1.07 billion in 2021. If RadioClash executes on its Niche Dominance scenario and establishes a new standard of care in a high-need area like pancreatic tumor ablation, it could attract acquisition interest in the high hundreds of millions to low billions (scenario, not a forecast). The value would be driven by the proprietary device, the clinical dataset, and the captured procedural revenue stream in a growing market for minimally invasive cancer treatments.
Data Accuracy: YELLOW -- The core opportunity thesis is based on company-stated focus areas and a reported partnership. The high-margin claim and specific growth catalysts lack third-party verification.
Sources
PUBLIC
[Voyage Houston Magazine] Meet Dr. John Qiao of RadioClash | https://voyagehouston.com/interview/meet-john-qiao-m-d-of-radioclash-ltd-co/
[Columbia Entrepreneurship, Nov 2021] RadioClash Wins Columbia-CareOne Healthcare Innovation Challenge | https://entrepreneurship.columbia.edu/2021/11/19/radioclash-wins-columbia-careone-healthcare-innovation-challenge-2021-columbia-venture-competition/
[YouTube, Sep 2025] RadioClash Company Overview and CTO Interview | https://www.youtube.com/watch?v=undefined
[SignalBase] RadioClash Inc Secures $1M Seed Funding | https://www.leadsontrees.com/news/radioclash-inc-secures-1m-seed-funding
[Startup Columbia, 2022] General 1 , Startup Columbia | https://www.startupcolumbia.org/fall-2022-competition
[The Org] Duane Bester - Founding Engineer at Handraise | https://theorg.com/org/handraise/org-chart/duane-bester
[BackTable] Dr. John Qiao on the BackTable VI Podcast | https://www.backtable.com/shows/vi/contributors/dr-john-qiao
Articles about RadioClash
- RadioClash's $1M Seed Puts a Probe on Late-Stage Pancreatic Cancer — The Houston startup is developing a minimally invasive electroporation device, betting on a combination therapy approach for solid tumors.